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Bigenic mouse models of focal segmental
glomerulosclerosis involving pairwise
interaction of CD2AP, Fyn, and synaptopodin
Tobias B. Huber,1 Christopher Kwoh,2 Hui Wu,1 Katsuhiko Asanuma,3 Markus Gödel,1
Björn Hartleben,1 Ken J. Blumer,4 Jeffrey H. Miner,2 Peter Mundel,3 and Andrey S. Shaw1
1Department

of Pathology and Immunology and 2Department of Medicine, Renal Division, Washington University School of Medicine, St. Louis, Missouri, USA.
3Department of Medicine, Mount Sinai School of Medicine, New York, New York, USA. 4Department of Cell Biology and Physiology,
Washington University School of Medicine, St. Louis, Missouri, USA.

Focal segmental glomerulosclerosis (FSGS) is the most common primary glomerular diagnosis resulting in
end-stage renal disease. Defects in several podocyte proteins have been implicated in the etiology of FSGS,
including podocin, a-actinin–4, CD2-associated protein (CD2AP), and TRPC6. Despite our growing understanding of genes involved in the pathogenesis of focal segmental sclerosis, the vast majority of patients with
this disease, even those with a familial linkage, lack a clear genetic diagnosis. Here, we tested whether combinations of genetic heterozygosity (bigenic heterozygosity) that alone do not result in clinical kidney disease could
function together to enhance susceptibility to glomerular damage and FSGS. Combinations of Cd2ap heterozygosity and heterozygosity of either synaptopodin (Synpo) or Fyn proto-oncogene (Fyn) but not kin of IRRE like 1
(Neph1) resulted in spontaneous proteinuria and in FSGS-like glomerular damage. These genetic interactions
were also reflected at a functional level, as we found that CD2AP associates with Fyn and Synpo but not with
Neph1. This demonstrates that bigenic heterozygosity can lead to FSGS and suggests that combined mutations
in 2 or multiple podocyte genes may be a common etiology for glomerular disease.
Introduction
Focal segmental glomerulosclerosis (FSGS) is a major cause of endstage renal disease and is increasing in frequency (1). The structure
affected in FSGS is the kidney glomerulus, which is composed of
capillaries that are involved in the filtration of blood. The diagnosis of FSGS is based on the clinical findings of proteinuria and specific histopathological changes, with areas of glomerular sclerosis
and glomerular tuft collapse that are both focal and segmental.
Focal refers to the finding that not all glomeruli are affected, and
segmental indicates that only a portion of the affected glomerulus
is sclerosed. While the etiology of most cases of FSGS is unknown,
the heterogeneous nature of these histologic changes suggests that
a combination of different factors is involved, including genetic
and environmental influences (2, 3).
The podocyte, the visceral epithelial cell of the glomerulus,
has taken center stage in research on the pathogenesis of FSGS.
Genetic studies in both human and mouse reveal that the development of FSGS is initiated by podocyte dysfunction (2). In humans,
mutations of the podocyte-specific gene nephrosis 2 homolog, podocin
(Nphs2) (encoding podocin) (4), the more ubiquitously expressed
cytoskeletal protein a-actinin–4 (5), and the ion channel protein
TRPC6 (6, 7) have been shown to impair podocyte function and
to cause an inherited form of FSGS. Mouse studies demonstrate
that the complete absence of either podocin (8) or a-actinin–4 (9)
results not in FSGS but in a severe podocyte dysfunction leading
Nonstandard abbreviations used: ARF, ADP-ribosylation factor; BUN, blood urea
nitrogen; CD2AP, CD2-associated protein; FSGS, focal segmental glomerulosclerosis;
Fyn, Fyn proto-oncogene; MAP, mean arterial pressure; Neph1, kin of IRRE like 1;
Nphs2, nephrosis 2 homolog, podocin; Synpo, synaptopodin.
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to a lethal nephrotic syndrome that occurs at or near birth. The
complete absence of other gene products that are either podocyte
specific, such as nephrin (10) and kin of IRRE like 1 (Neph1) (11),
or more ubiquitously expressed, such as CD2-associated protein
(CD2AP) (12), can also lead to severe podocyte dysfunction and
congenital nephrotic syndrome.
These studies suggest that the degree of podocyte dysfunction
determines whether congenital nephrotic syndrome or FSGS
occurs. Severe impairment of podocyte function would lead to
perinatal glomerular failure while a more modest impairment
would require additional environmental factors before focal and
segmental changes in glomeruli could occur (2).
In this study, we were interested to explore whether combinations of heterozygosity for different podocyte-relevant genes
would increase the risk for FSGS. We therefore crossed mice
heterozygous for Cd2ap with mice that are heterozygous for the
signaling protein Fyn proto-oncogene (Fyn), the long isoform of the
actin-bundling protein synaptopodin (Synpo), or the slit diaphragm
protein Neph1. While Cd2ap-null mice develop nephrotic syndrome and end-stage renal disease early in life, the clinical phenotype of Cd2ap heterozygous animals is relatively unremarkable
(13). However, bigenic heterozygosity of Cd2ap with Fyn or Synpo
but not Neph1 resulted in a significantly increased incidence of
proteinuria and pathological changes consistent with FSGS. This
suggests that combined mutations of genes in pathways involving
CD2AP, Fyn, and Synpo may account for a significant fraction of
patients with FSGS.
Results
Bigenic heterozygosity of Cd2ap and Fyn leads to proteinuria. We first
bred Cd2ap heterozygous mice to Fyn-deficient mice on a pure
C57BL/6J background. Fyn is a Src-family tyrosine kinase that is
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Figure 1
CD2AP haploinsufficiency enhances proteinuria in Fyn-deficient mice. (A) Mice were tested monthly for proteinuria. The
incidence of proteinuria is depicted as both percentages and
absolute numbers for the indicated mouse genotypes followed to up to 12 months of age. The onset of proteinuria is
shown below for each genotype in months ± SEM. *Statistical
significance. (B) Sections of formalin-fixed kidney cortex from
5- to 8-month-old mice were stained with H&E and with PAS.
In Fyn–/– mice, most glomeruli were normal (top right). Representative glomeruli from Fyn+/–Cd2ap+/– mice (middle row)
or Fyn–/–Cd2ap+/– mice (bottom row) taken 2 months after the
onset of proteinuria reveal mesangial hypercellularity and
segmental sclerosis or global sclerosis in some glomeruli.
Magnification, ×400.

expressed in podocytes, where it has been shown to phosphorylate
the slit diaphragm component nephrin (14). While Yu et al. reported that most Fyn–/– mice develop mild proteinuria by 6 months of
age, Verma et al. were unable to detect any significant proteinuria
in Fyn–/– mice (14, 15). Both groups found no histological abnormalities but did demonstrate podocyte foot process effacement.
Lastly, Fyn+/– mice do not develop proteinuria or display any light
or electron microscopic abnormalities (15).
Five mouse genotypes were generated and followed up to 12
months: Fyn +/+Cd2ap +/–, Fyn +/–Cd2ap +/+, Fyn –/–Cd2ap +/+, Fyn +/–
Cd2ap+/–, and Fyn–/–Cd2ap+/–. Because proteinuria is the earliest
and most sensitive clinical indicator of glomerular dysfunction,
proteinuria was used as the primary end-point for this study.
Mice were tested monthly for the presence of albumin in the
urine and followed to up to 12 months of age. Because some
wild-type mice develop low-grade proteinuria at advanced ages,
varying with genetic background (16–18), we used only littermates for controls. Proteinuric animals were typically sacrificed
1338
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within 1 month of detection. In our colony, about 31%
of Fyn–/– mice developed proteinuria, with an average age
of onset of 8 months of age, a phenotype that is intermediate between those in the 2 previous studies. Consistent
with what was reported previously, Fyn+/– mice did not
develop proteinuria (14, 15).
In the presence of CD2AP haploinsufficiency, 56% of
Fyn+/– mice developed proteinuria (P < 0.01 relative to
Fyn+/– alone) while the rate of proteinuria in Fyn–/– mice
was increased to 100% (Figure 1A; P < 0.0025). In addition, CD2AP haploinsufficiency significantly accelerated the onset of proteinuria from 8 months of age to 5
months of age (P < 0.05). Near the onset of proteinuria,
the serum blood urea nitrogen (BUN) (16.6 ± 1.3 mg/dl)
and creatinine (0.57 ± 0.03 mg/dl) levels of Fyn+/–Cd2ap+/–
and Fyn–/–Cd2ap+/– mice were similar to those of wild-type
mice (C57BL/6 background). Five mice were measured
2–3 months after onset of proteinuria, with consistently
elevated creatinine levels (0.7 ± 0.03 mg/dl) and slightly
elevated BUN levels (18.8 ± 3.1 mg/dl). Proteinuria progressed in these mice from 70 ± 12 mg/dl to 200 ± 41 mg/dl
(n = 5) over this period of time.
Light microscopic examination of Fyn–/+ and Fyn–/– were
consistent with previous studies and showed no significant or only minor histological changes, such as mesangial hypercellularity in some Fyn–/– glomeruli. However, in
the presence of CD2AP haploinsufficiency, there were significant
pathological glomerular changes, some of which were consistent
with FSGS. The most common finding was glomerular hypercellularity with mesangial expansion seen in many but not all glomeruli
(Figure 1B). There were occasional sclerotic glomeruli and glomeruli with segmental sclerosis (Figure 1B). There was a tendency
toward more significant levels of sclerosis in the Fyn–/–Cd2ap+/–
mice compared with Fyn+/–Cd2ap+/– mice. The histological changes
correlated with the degree of proteinuria.
Electron microscopic examination of Fyn+/– and Fyn–/– kidneys
demonstrated mild changes, with foot process coarsening, fusion,
and effacement consistent with previous reports. In the presence
of CD2AP haploinsufficiency, these changes were more extensive
(Figure 2). In proteinuric animals, electron-dense subepithelial
and mesangial deposits were detected (Figure 2).
Bigenic heterozygosity of Cd2ap and Synpo leads to proteinuria. We
next bred Cd2ap heterozygous mice to Synpo-deficient mice
on a pure 129 background. Synpo is an actin-bundling protein
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Figure 2
Electron micrograph images from combined heterozygous
mice between Cd2ap and Fyn. (A) Representative electron
microscopic images showing normal foot process architecture in wild-type (left panel), Cd2ap+/– (middle panel), and
Fyn+/– (right panel) podocytes. (B) Electron micrographs
from proteinuric Fyn–/– mice revealed only some coarsening
of the foot processes. (C and D) Fyn+/–Cd2ap+/– mice (C)
and Fyn–/–Cd2ap+/– mice (D) exhibited foot process effacement in some but not all areas. Magnification, ×12,000.

expressed specifically in podocytes and in telencephalic dendrites
(19). There are 3 isoforms of Synpo (Synpo-long, Synpo-short,
and Synpo-T) that are generated by alternative RNA splicing
(20). Recently generated Synpo–/– mice lack the Synpo-short and
Synpo-long expression but still express Synpo-T isoform in podocytes (20). While these mice exhibit neuronal defects, no spontaneous kidney phenotype was detected (20, 21).
Four genotypes were generated: Synpo +/+Cd2ap +/–, Synpo –/–
Cd2ap+/+, Synpo+/–Cd2ap+/–, and Synpo–/–Cd2ap+/–. The animals were
evaluated in the same manner as the Fyn/Cd2ap mice. Consistent
with a previous report (20), we did not detect any proteinuria in
Synpo-deficient or Synpo-heterozygous animals over the year of
observation (Figure 3A). In the presence of CD2AP haploinsufficiency, however, 58% of Synpo–/– and 29% of Synpo+/– mice developed proteinuria. (P < 0.00001 and P < 0.006 respectively) (Figure 3A). The average age of onset of proteinuria was 7–8 months
and was not significantly different between Synpo+/–Cd2ap+/– and
Synpo–/–Cd2ap+/– mice (Figure 3A). Synpo+/–Cd2ap+/– and Synpo–/–
Cd2ap+/– mice measured near the onset of proteinuria had serum
BUN (17.2 ± 0.9 mg/dl) and creatinine (0.46 ± 0.02 mg/dl) levels (n = 27) that were similar to those of wild-type mice (129
background). Four mice were measured 2–3 months after onset
of proteinuria, with elevated BUN (50.4 ± 16.5 mg/dl) and creatinine levels (0.7 ± 0.13 mg/dl). Proteinuria increased consistently from 90 ± 6 mg/dl to 240 ± 44 mg/dl when mice were
followed for 2–3 months after onset of proteinuria (n = 6). As
with the Cd2ap/Fyn mice, these data indicate a progression of
disease over time with worsening severity of proteinuria, leading
to an eventual decline in glomerular filtration and significant
glomerulosclerotic changes.
The Journal of Clinical Investigation

Light microscopic examination of Synpo+/– and Synpo–/–
kidneys did not reveal any obvious histological abnormalities (Figure 3B), but pathological changes were
obvious in Synpo+/–Cd2ap+/– and Synpo–/–Cd2ap+/– kidneys
(Figure 3B). As with the Fyn/CD2AP mice, these changes
mainly involved hypercellular glomeruli with expanded
mesangium in some but not all glomeruli. In addition,
there were occasional glomeruli that were either completely or segmentally sclerosed (Figure 3B).
Electron microscopic examination of the kidneys from
these mice showed no obvious changes in kidneys from
Synpo+/– or Synpo–/– mice. In the presence of CD2AP haploinsufficiency, however, both Synpo+/– and Synpo–/– mice
demonstrated sequential changes in the foot process
architecture, consisting of coarsening and effacement
of foot processes (Figure 4, B and C). We noted the presence of electron-dense deposits within glomerular basement membranes and mesangium (Figure 4B). Similar
deposits and IgG staining have been seen in older (> 9
month old) Cd2ap heterozygous mice, as previously shown (13).
Electron microscopy and immunofluorescence staining for IgG
on 6- to 9-month-old Cd2ap+/–Synpo+/– (n = 15) and Cd2ap+/–Synpo–/–
mice (n = 26) (data not shown) showed positive IgG staining in 13
out of 25 proteinuric mice and 8 out of 16 nonproteinuric mice.
Electron-dense deposits were seen in 8 out of 23 proteinuric
mice and 4 out of 16 nonproteinuric mice. Since the presence
or absence of electron-dense deposits and IgG staining does not
appear to correlate very well with proteinuria, we suspect that the
presence of electron-dense deposits and positive IgG staining is
related to the Cd2ap heterozygous background of the mice and
not to the combined heterozygosity.
CD2AP haploinsufficiency combined with Neph1 heterozygosity. Neph1
is a transmembrane receptor closely related to nephrin, expressed
in podocytes, brain, and smooth muscle of liver, lung, and heart
(11). In the podocyte, Neph1 localizes to the slit diaphragm and
is thought to function like nephrin in maintenance of the slit diaphragm (22, 23). Neph1-deficient animals, generated by retroviral
insertion, are born with congenital nephrotic syndrome and usually die in the perinatal period (11).
Neph1+/– animals were bred to Cd2ap heterozygous animals to
determine whether combined heterozygosity would contribute
to a glomerular phenotype. Because of the mixed backgrounds
of these animals, we compared only littermates, and the results
were quite decisive: Neph1+/– animals did not exhibit any obvious kidney abnormalities (data not shown). Zero of 16 Neph1+/–
Cd2ap+/– mice developed proteinuria over the 12-month observation period, and none of these mice exhibited any histologic
abnormalities before 9 months of age (data not shown). Since
bigenic heterozygosity of Neph1 and Cd2ap did not result in pro-
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Figure 3
Bigenic Cd2ap and Synpo heterozygosity lead to proteinuria
and FSGS. (A) Mice were screened monthly for proteinuria.
The incidence of proteinuria is depicted as both percentages
and absolute numbers for the indicated mouse genotypes followed for up to 12 months. The onset of proteinuria is shown
below for each proteinuric genotype in months ± SEM and
did not differ among genotypes. *Statistical significance. (B)
Sections of formalin-fixed kidney cortex from 6- to 9-monthold mice were stained with H&E and with PAS. In wild-type,
Synpo–/–, and CD2AP +/– mice, nearly all glomeruli were normal
(top panel). Representative glomeruli from Synpo+/–Cd2ap+/–
mice (middle row) or Synpo–/–Cd2ap+/– mice (bottom row)
2 months after the onset of proteinuria showed mesangial
hypercellularity and segmental or global sclerosis in some but
not all glomeruli. Magnification, ×400.

teinuria, the combined heterozygous effect of Cd2ap with Fyn
and Synpo appears to be specific.
Cd2ap heterozygosity does not alter blood pressure. Since CD2AP is
widely expressed, including in blood vessels, myocardium, and
renal collecting duct, we wanted to exclude the possibility that
Cd2ap heterozygosity accelerated glomerular disease by inducing hypertension. Mean arterial pressure (MAP) was measured
using intraarterial pressure catheters in 4-month-old male wildtype and Cd2ap heterozygous animals (n = 7). Blood pressure was
found to be normal and similar between Cd2ap heterozygous
mice (MAP = 70 mmHg) and littermate wild-type and wild-type
controls (MAP = 71 mmHg).
CD2AP interacts with Fyn and Synpo, but not with Neph1. The above
results showing genetic epistasis between CD2AP and Fyn and
between CD2AP and Synpo suggested that these proteins may
function in the same pathway. We were therefore interested to
determine whether CD2AP could physically interact with either
Synpo or Fyn. To test for interactions between CD2AP and Fyn,
immunoprecipitates prepared from human kidney cell-line
lysate (Figure 5A) or rat glomerular lysates (Figure 5A) using
antibodies to Fyn (polyclonal antibody) were immunoblotted
1340
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with an antiserum to CD2AP. CD2AP was easily detected
in Fyn but not in control antibody immunoprecipitates.
This demonstrates for what we believe is the first time
that endogenous CD2AP and Fyn form a constitutive
complex (Figure 5A).
To test for an interaction between Synpo and CD2AP,
immunoprecipitates were prepared from podocyte cell
lysates using Synpo antibodies. Immunoblotting with
antibodies to CD2AP showed the presence of CD2AP in
Synpo lysates (Figure 5B). The converse was also true.
Immunoprecipitates prepared with CD2AP antibodies
and immunoblotted with antibodies to Synpo also demonstrated an interaction (Figure 5B).
To map the interacting domains, 2 mutated forms of
CD2AP were used. The structure of CD2AP is notable for 3
SH3 domains at the N terminus and multiple proline-rich
sequences at the C terminus. Constructs lacking the SH3
domains or the proline-rich sequences were both tested for
Synpo binding. While Synpo (Synpo-long) interacted with
wild-type CD2AP and a mutated form of CD2AP lacking
the proline sequences, there was no detectable interaction
of Synpo (Synpo-long) with the mutated form of CD2AP
lacking the SH3 domains (Figure 6A). This suggests that the SH3
domains of CD2AP mediate the interaction with Synpo-long, presumably by binding to proline-rich sequences in Synpo.
To test whether the interaction between the SH3 domains of
CD2AP and Synpo is direct, far Western blot experiments were
performed. FLAG-tagged Synpo-long and FLAG-tagged GFP as
control were blotted on a nitrocellulose membrane and subsequently incubated with biotinylated, recombinant CD2AP
protein containing all 3 SH3 domains. As shown in Figure 6B,
the CD2AP SH3 domains specifically bound to Synpo-long,
indicating a direct SH3 domain–mediated interaction between
CD2AP and Synpo.
Recently, the existence of 3 Synpo isoforms, Synpo-long, Synposhort, and Synpo-T, has been described (20). We therefore tested
whether CD2AP interacts with all isoforms of Synpo. Figure 6C
shows that CD2AP can be coimmunoprecipitated with Synpolong, Synpo-short, and Synpo-T (Figure 6C).
Lastly, since CD2AP is known to interact with nephrin, we
were interested to know whether CD2AP interacts with Neph1.
Immunoprecipitates were prepared using lysates from cells coexpressing CD2AP with epitope-tagged Neph1 or epitope-tagged

http://www.jci.org

Volume 116

Number 5

May 2006

Downloaded on August 5, 2013. The Journal of Clinical Investigation. More information at www.jci.org/articles/view/27400

research article
Figure 4
Electron micrograph images from combined heterozygous mice
between Cd2ap and Synpo. (A) Representative electron microscopic
images showing normal foot process architecture in wild-type (left panel)
or Cd2ap+/– mice (right panel). (B) Electron micrographs from proteinuric Synpo+/–CD2AP+/– showed extensive foot process effacement as
well as subepithelial deposits (arrows). (C) Electron micrographs from
proteinuric Synpo–/–CD2AP+/– showed findings similar to those shown in
B, with foot process effacement. Magnification, ×12,000.

nephrin. While immunoblotting of CD2AP immunoprecipitates
showed the presence of nephrin, no interaction between CD2AP
and Neph1 was detected under the same conditions (Figure 6E).

FSGS have homozygous missense mutations, suggesting that the
mutation causes a weak loss of function that is only able to cause
disease when mutations of both alleles are present (27). Importantly, cases of increased disease susceptibility have been reported
with mutations of only 1 podocin allele, suggesting involvement
of another genetic locus (4, 26).
Mutations in the gene encoding a-actinin–4 are linked to an
autosomal dominant form of FSGS in which the clinical presentation is also widely variable (5). In these patients, the disease has a
late onset (first occurring in early adulthood) and is incompletely
penetrant (5). Mice that are completely deficient for a-actinin–4
develop a severe congenital nephrotic syndrome (9) while mice
that are heterozygous for the dominant acting K228E allele do
not display any overt disease (28). These observations strongly
suggest that environmental as well as other genetic factors may
play important roles in determining whether disease occurs when
a single copy of the disease-causing allele is present.
Here, we focused on bigenic heterozygosity of Cd2ap. We previously showed that mice that are heterozygous for Cd2ap develop
pathological changes after 9 months of age but not proteinuria
(13). Cd2ap heterozygous mice, however, have an increased sensitivity to nephrotoxic injury (13). Given the mild phenotype of Cd2ap
heterozygous mice, we speculated that combined heterozygous
mutations in Cd2ap and other associated proteins might increase
susceptibility to podocyte dysfunction.
We first focused on combining Cd2ap heterozygosity with deficiency of the Src family tyrosine kinase Fyn. While Fyn+/– mice are

Discussion
Here, we tested whether combined genetic heterozygosity might
play a role in the etiology of FSGS. Given the limited number
of proteins implicated in podocyte-specific functions, a simple
approach was to directly test whether combined heterozygosity of
podocyte-relevant genes might cooperate together to cause podocyte dysfunction and, subsequently, glomerular disease. CD2AP is
a scaffold protein that interacts with a variety of proteins, including slit diaphragm, signaling, and cytoskeletal proteins (24). We
speculated that mutations in Cd2ap might sensitize the podocyte
to mutations in a wide variety of different genes. We
found that heterozygosity of Cd2ap combined with heterozygosity of Synpo or Fyn led to a significant incidence
of glomerular dysfunction as evidenced by proteinuria
and pathological changes consistent with FSGS.
Recent progress has helped to illuminate the important
role of the podocyte in the etiology of glomerular diseases
like FSGS (2, 3). Mouse knockout models demonstrate
that deficiencies of either podocyte-specific genes (encoding for podocin, ref. 8; nephrin, ref. 25; and Neph1, ref.
11) or more ubiquitously expressed genes (encoding for
a-actinin–4, ref. 9; CD2AP, ref. 12; and Fyn, ref. 15) can
result in podocyte dysfunction leading to a severe con- Figure 5
genital nephrotic syndrome. Genetic studies in humans CD2AP forms an endogenous complex with Fyn and Synpo. (A) Endogenous
suggest that less severe mutations in some of these genes CD2AP interacts with endogenous Fyn in cells (upper panel) and rat glomeruli
may be responsible for a more variable pattern of disease (lower panel). Lysates were prepared from HEK 293 cells or isolated rat glomthat may be responsible for some cases of familial and eruli, respectively (input lysate, 25 ml out of 800 ml; lane 1). Immunoprecipitates
were prepared with a control antibody (rabbit serum, lane 2) or with polyclonal
idiopathic FSGS (26).
antisera to Fyn (lane 3). Immunoblotting was performed with a polyclonal
Podocin mutations were first described in an autosomal
antibody to CD2AP. (B) Endogenous CD2AP interacts with endogenous
recessive form of FSGS that occurs with variable onset in Synpo in podocytes. Lysates were prepared from differentiated podocytes.
children between 2 and 10 years of age (4). Over 40 differ- Immunoprecipitates were prepared with a control antibody and anti-Synpo
ent mutations in podocin have now been described (27). (upper panel) or anti-CD2AP (lower panel) antibodies and immunoblotted with
Most of the affected patients with autosomal recessive anti-Synpo or anti-CD2AP.
The Journal of Clinical Investigation
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about 31% of Fyn–/– mice develop proteinuria by 12 months of age. This
value, which is intermediate between
the results of the 2 previous studies,
suggests that other factors may be
involved in the initiation and/or severity of proteinuria. However, the combination of CD2AP haploinsufficiency
with Fyn deficiency clearly accentuated
disease, as 100% of these animals developed proteinuria. A gene dosage effect
was also apparent, since mice that
were heterozygous for Cd2ap and null
for Fyn developed proteinuria at a rate
that was almost double the rate of combined Cd2ap+/– and Fyn+/– mice. Lastly, it
should be noted that bigenic heterozygosity resulted in pathological changes
that were not present in the Fyn+/– or
CD2AP +/– mice.
Our experiments with the Synpodeficient mice implicate, for what we
believe is the first time, a role for Synpo
in the pathogenesis of FSGS. Synpo is
an actin-bundling protein that is specifically expressed in podocytes and in
certain neurons in the brain (19). Synpo
knockout mice exhibit neuronal defects
but do not exhibit any spontaneous kidney abnormality (20, 21). Recently, the
discovery of multiple Synpo isoforms
and the fact that the shortest Synpo
isoform (Synpo-T) is still expressed in
Figure 6
CD2AP SH3 domains interact directly with Synpo, but CD2AP does not interact with Neph1. (A) the Synpo knockout suggest that this
FLAG-tagged Synpo (Synpo-long) was coexpressed with myc-tagged proteins, including full- isoform might be compensating for the
length CD2AP (lane 1, CD2AP FL), CD2AP lacking the SH3 domains (lane 2, DSH3 domains), and loss of the larger 2 isoforms in podoCD2AP lacking the proline-rich domains (lane 3, DPR domains). Anti-FLAG immunoprecipitates
cytes (20). The in vivo functionality of
were immunoblotted with an anti-myc antibody (upper panel). The expression of wild-type and
Synpo-T
is not entirely clear, but in any
mutated CD2AP proteins (input lysate; anti-myc) and Synpo is shown in the middle and lower
case,
our
work establishes that Synpopanels, respectively. (B) FLAG-tagged Synpo (lane 1, FLAG–Synpo-long) and FLAG-tagged GFP
(lane 2) were overexpressed, and anti-FLAG immunoprecipitates were blotted with recombinant, T is unable to fully compensate in the
biotinylated GST-CD2AP fusion protein containing the 3 SH3 domains (left panel) or immunoblotted presence of CD2AP haploinsufficiency.
with anti-FLAG antibody (right panel). (C) FLAG-tagged GFP (lane 1, control), FLAG-tagged
It should be emphasized that the relaSynpo-long (lane 2), FLAG-tagged Synpo-short (lane 3), and FLAG-tagged Synpo-T (lane 4) were tively mild pathological changes seen
coexpressed with myc-tagged full-length CD2AP. Immunoprecipitates were prepared with an anti- here are partially related to the way
FLAG antibody and immunoblotted with an anti-myc antibody (upper panel). (D) Neph1–yellow
the experiment was designed. We used
fluorescent protein (Neph1-YFP) was coexpressed with myc-tagged full-length CD2AP (lane 1)
proteinuria
as the end-point and sacor myc-tagged nephrin (lane 2). Anti-myc immunoprecipitates were immunoblotted with anti-YFP
antibody (upper panel). The expression of Neph1-YFP input lysate and myc-tagged nephrin or rificed mice as soon as proteinuria was
CD2AP controls is shown in the middle and lower panels, respectively. (E) Neph1-YFP (lane 1) and confirmed. Since we screened mice only
myc-nephrin (lane 2) were coexpressed with full-length FLAG-tagged CD2AP. Immunoprecipitates monthly, the variability of proteinuria
of FLAG-CD2AP were immunoblotted with anti-myc and anti-YFP antibodies. Neph1-YFP or myc- and pathological changes may have been
nephrin input lysates (anti-myc, anti-YFP) and CD2AP expression are demonstrated in the middle due to variable length of time proteinand lower panels, respectively.
uria was present. When a few proteinuric animals were followed for several
months, the proteinuria and pathologiphenotypically and histologically normal, 2 groups have demon- cal changes progressed rapidly, leading to renal dysfunction and a
strated that podocyte foot processes are abnormal in Fyn–/– mice significant level of glomerulosclerosis.
These studies demonstrating genetic epistasis among CD2AP,
(14, 15). The occurrence of proteinuria in these mice, however, is
controversial, with DeFranco’s group (15) reporting proteinuria Fyn, and Synpo imply that these proteins might interact with each
in most mice by 6 months of age and Holzman’s group (14) not other. We showed, for what we believe is the first time, endogenous
reporting any proteinuria in these mice. In our study, we found associations of CD2AP with Synpo and Fyn. The association of Fyn
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with CD2AP is probably mediated by the SH3 domain of Fyn binding to proline sequences in CD2AP, as a previous report showed
that the SH3 domains of Fyn, Src, and Yes could bind to CD2AP
in vitro (29). Our study also demonstrated that Synpo and CD2AP
form a protein complex. Mapping studies revealed that CD2AP and
Synpo can directly interact and that this interaction is mediated by
the SH3 domains of CD2AP, presumably by binding to proline-rich
segments of Synpo. The fact that CD2AP binds to the nonoverlapping isoforms Synpo-short and Synpo-T suggests that there are at
least 2 different proline-rich segments that can bind to CD2AP.
These data suggest that CD2AP, Fyn, and Synpo act in the same
genetic pathway to maintain podocyte integrity. While the specific pathway is unclear, clues have emerged from the wide variety
of proteins that are known to associate with CD2AP. For instance,
CD2AP has been shown to interact with the slit diaphragm proteins podocin (30) and nephrin (31). A putative role for CD2AP
in linking the slit diaphragm to the cortical actin cytoskeleton
is suggested by associations of CD2AP with actin-capping protein (32), cortactin (33, 34), and the GTPase-activating protein
for ADP-ribosylation factor (ARF) family G proteins, ASAP1 (35).
CD2AP is also implicated in intracellular trafficking by its known
interactions with proteins, such as synaptojanin, Rab4, and AP-2
(36, 37). A role for CD2AP in mediating ubiquitination and degradation in the lysosome is indicated by its known association with
the ubiquitin ligase Cbl (38, 39).
In this study, we identified 2 new interacting partners for CD2AP,
Fyn, and Synpo. As Fyn is known to tyrosine phosphorylate nephrin, it is exciting to speculate that the slit diaphragm is a type of
signaling receptor and that CD2AP functions to orchestrate such
complex processes as endocytosis and turnover of slit diaphragm
components, establishments of cell polarity, and antiapoptotic signaling. The interaction between CD2AP and Synpo reinforces the
idea that CD2AP plays a central role in regulating the actin cytoskeleton. We speculate that combined heterozygosity of CD2AP
and many other proteins in the slit diaphragm signalosome may
contribute to susceptibility to FSGS.
It is somewhat surprising that there are only a few published
models where bigenic heterozygosity has been shown to directly
lead to disease. These include congenital nonsyndromic hearing
impairment (40), human insulin resistance (41, 42), inherited disorders of fatty acid b-oxidation (43), and polycystic kidney disease
(44). To our knowledge, this is the first description of combined
heterozygosity causing any kind of glomerular disease. Koziell et
al. reported a “triallelic” phenotype of 4 patients with homozygous
mutations in either Nphs1 (nephrin) or Nphs2 (podocin), with an
additional mutation in 1 allele of either Nphs1 (nephrin) or Nphs2
(podocin) (45). Genetic epistasis between nephrin and podocin is
suggested by the combined effects of the 3 mutations (45). It is not
clear, however, how the presence of the heterozygous allele influences the phenotype or the course of disease. But this reinforces
the idea that the presence of additional mutations may play a role
in susceptibility to FSGS.
The initial therapy for most cases of FSGS involves steroids or
other potent immunosuppressants; however, the FSGS seen in
established disease-causing mutations has typically been poorly
responsive to steroids (46). Only a small fraction of the cases of steroid-resistant FSGS or familial FSGS have identified mutations (2).
Thus, many of the remainder are likely to have some combinations
of heterozygous mutations, as demonstrated in our models. The
identification of such genes and alleles involved in familial FSGS
The Journal of Clinical Investigation

will therefore aid the clinician in choosing which patients are likely
to benefit from potentially toxic immunosuppressants. The future
focus of glomerular diseases, such as FSGS, should expand from
the evaluation of individual genes to the examination of the impact
of many genes in combination. The use of combined mutational
mouse models may allow us to identify genes that may act in concert
with other genetic mutations to increase disease susceptibility.
Methods
Materials and reagents. The immortalized podocyte cell line has been
described in detail (47). Synpo cDNA constructs (20), CD2AP- and nephrin-cDNA constructs (31) have been published previously. Antibodies to
Synpo (20), to CD2AP (31), and to Fyn (48) have been described. Anti-Myc
Tag (clone 4A6; Upstate USA Inc.), anti-FLAG M2-agarose (Sigma-Aldrich),
monoclonal anti-GFP antibody ( JL-8, BD Biosciences), protein G sepharose (Sigma-Aldrich), and Sulfo-NHS-LC-Biotin (Pierce Biotechnology)
were purchased as indicated.
Mice breeding. CD2AP-deficient mice were maintained in our colony as
heterozygotes and genotyped as previously described (12). Cd2ap+/– mice
were backcrossed (>10 generations) to a C57BL/6J background or maintained on a pure 129Sv background.
Fyn-deficient mice were obtained from Jackson Laboratory, maintained
on a C57BL/6J background in our laboratory, and genotyped per their
published protocol. Synpo-deficient mice on a 129/Ola background (20)
were genotyped as previously described (21). Neph1-deficient mice were
obtained from Lexicon Genetics Inc. on a mixed 129/C57BL/6J-Tyrc-brd
background and genotyped as previously published (11).
Synpo/CD2AP and Fyn/CD2AP colonies were maintained on a pure
129 or C57BL/6J background, respectively. For all experiments, only littermates derived from the intercrossing of the 2 gene-deficient lines were
used. In the case of the Neph1 and CD2AP intercrossing, we used colonies with a mixed C57BL/6J and 129Sv background. However, again we
compared only littermates.
All animal studies reported here were approved by the Washington University Animal Studies Committee.
Urine and serum protein and creatinine. Urine was collected monthly and
tested for proteinuria using SDS-PAGE and known quantities of BSA as
controls. An albumin concentration of 30 mg/dl was considered positive.
Results correlated with measurements of urine protein performed using a
Roche Cobas Mira Plus analyzer (Roche Diagnostics Corp.).
Histology. Mice were sacrificed within a month of scoring positive for
proteinuria. After dissection, kidneys were rinsed in phosphate-buffered
saline, fixed overnight in formalin, and submitted to the Histopathology
Laboratory at Washington University Medical School for paraffin embedding, sectioning, and staining with PAS and H&E
Electron microscopy. After dissection, renal cortex was fixed in 2.5% glutaraldehyde in 0.1 M Na cacodylate, stained in OsO4, dehydrated in ethanol,
embedded in PolyBed 812 (Polysciences Inc.), sectioned on an ultramicrotom (Ultra Cut, Reichert-Jung), poststained in uranyl acetate and lead
citrate, then viewed on a Zeiss 902 Electron Microscope in the Cell Biology
Department of Washington University.
Blood pressure measurements. Mice were anesthetized with a 1.5% isoflurane/oxygen mixture administered with a vaporizer (Ohmeda Isotec 3,
BOC Health Care). As previously described (49), we recorded heart rate
and MAP by catheterizing the right common carotid artery with a Millar
1.4 French blood pressure probe and transducer (Millar Instruments Inc.)
coupled to a PowerLab/4SP data-acquisition system (ADInstruments) and
passing the probe into the ascending aorta.
Coimmunoprecipitation. HEK 293T cells were transiently transfected with
Lipofectamine (Invitrogen Corp.). After incubation for 24 hours, cells were
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washed twice and lysed in a 1% Triton X-100 lysis buffer. To test the coimmunoprecipitation of nephrin and Neph1 with CD2AP, we used a lysis
buffer containing 1% digitonin (31). After centrifugation (15,000 g, 15 min,
4°C), cell lysates containing equal amounts of total protein were incubated
for 1 hour at 4°C with the appropriate antibody followed by incubation
with 40 ml of protein G sepharose beads for approximately 1 hour. The
beads were washed extensively with lysis buffer, and bound proteins were
resolved by 10% SDS-PAGE, transferred to nitrocellulose membranes, and
immunoblotted with specific antibodies. For coimmunoprecipitation of
endogenous proteins, lysates were prepared from 293T cells, differentiated
mouse podocytes, or rat glomerular lysates. After centrifugation (15,000 g,
15 minutes, 4°C) and ultracentrifugation (100,000 g, 30 minutes, 4°C),
cell lysates containing equal amounts of total protein were precleared with
protein G sepharose and then incubated for 1 hour at 4°C with the indicated antiserum, followed by incubation with 40 ml of protein G sepharose
beads for approximately 1 hour. The beads were washed extensively with
lysis buffer, and bound proteins were resolved by 10% SDS-PAGE.
Far Western blot. Immunoprecipitates of FLAG-tagged Synpo-long and
FLAG-tagged GFP as control were run on SDS-PAGE and then transferred
onto a nitrocellulose membrane. Blots were blocked in PBS–Tween 20
containing 5% BSA and then incubated with 100 mg/ml of biotinylated
CD2AP SH3 domains containing GST fusion protein in the blocking buffer at 4°C. The blots were probed with HRP-conjugated streptavidin and
then subjected to enhanced chemiluminescence.
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